Clinical Trials
Study of MK-2870 as a single agent and + Pembrolizumab vs Physician's choice in patients with HR+/HER- breast cancer
Disease Type: Breast
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville